Astellas Pharma Stock Soars 7.49%, Hits Intraday High of JPY 2,283.00

Astellas Pharma, Inc. has experienced a significant uptick in its stock performance, gaining 7.49% on May 29, 2026. The stock reached an intraday high of JPY 2,283.00, reflecting strong market activity. This performance stands in contrast to the Japan Nikkei 225, which rose by 2.53% on the same day. Over the past year, Astellas Pharma has delivered a remarkable return of 61.51%, although it has lagged behind the Nikkei 225's 72.58% gain. Year-to-date, the stock has increased by 9.08%, while its three-year performance shows a slight decline of 0.57%. In terms of financial health, the company boasts a robust return on equity (ROE) of 18.31% and a strong EBIT to interest ratio of 42.73, indicating its ability to manage debt effectively. Astellas Pharma's net sales have grown by 10.4%, and it has reported positive results for the last two consecutive quarters. With a market capitalization of JPY 4,131,461 million, the company continues to maintain a competitive position within the pharmaceuticals and biotechnology industry.